Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+antibodies

34 Results

Sort By:

Generative Language Model for Antibody Sequence Design (IgLM)

Unmet NeedMonoclonal antibody therapies have become an extremely popular and effective treatment route for cancer, rheumatoid arthritis, and infectious diseases. At present, there are over 100 FDA approved monoclonal antibody therapies with many more in late stage clinical trials (see Nature). One approach that is commonly used to generate monoclonal...

Published: 4/24/2026 | Inventor(s): Jeffrey Gray, Jeffrey Ruffolo, Richard Shuai

Keywords(s):

Category(s): Technology Classifications > Computers, Electronics & Software > Algorithms, Technology Classifications > Computers, Electronics & Software > Artificial Intelligence, Technology Classifications > Computers, Electronics & Software > Machine Learning, Technology Classifications > Therapeutic Modalities > Antibodies, Copyright

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 4/23/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Monoclonal Antibody for Cancer Metastasis

Unmet Need· It is projected that there will be about 1.9 million cancer cases, and 6 thousand cancer deaths within the US in the year 2023 (Siegel, 2021). mAb immunotherapy has been found to be less damaging and less invasive to rapidly dividing normal tissues when compared to current tumor therapy treatments such as surgery, radiation, and chemotherapy....

Published: 4/24/2026 | Inventor(s): Andrew Ewald, Matthew Dunworth, Shannon Radomski, Livia Casciola-Rosen, Antony Rosen

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Biomarkers, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Human Broadly Neutralizing Monoclonal Antibodies associated with Hepatitis C Virus Clearance

Hepatitis C antibodies for the development of vaccinesJHU Ref #: C17709Value Proposition:· Comprehensive panel of monoclonal and broadly-neutralizing antibodies against HCV· Potential treatment for HCV infection· Key bNAb-E2 interactions identified· Candidates for discovery of HCV vaccine antigensUnmet NeedHepatitis C virus (HCV)...

Published: 4/24/2026 | Inventor(s): Justin Bailey, Clinton Ogega

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > Hepatitis C Virus, Clinical and Disease Specializations > Infectious Diseases > Hepatitis C Virus (HCV), Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Technology Classifications > Therapeutic Modalities > Vaccines

Therapeutic KCNK9 Antibody

Value PropositionFirst-in-Class Targeting of a Novel Oncogenic Ion Channel: Inhibiting KCNK9 represents a new therapeutic modality in cancers where traditional approachesTumor-Specific Overexpression Enables Selectivity: KCNK9 is overexpressed in various tumors (e.g., breast, gastric, lung) but has limited expression in most normal tissuesPro-Apoptotic...

Published: 4/24/2026 | Inventor(s): John Laterra, Amy Fulton

Keywords(s):

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer, Clinical and Disease Specializations > Oncology > Gastric Cancer, Technology Classifications > Therapeutic Modalities > Antibodies

Novel monoclonal antibody inhibitors targeting potassium channel KCNK9

Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...

Published: 4/23/2026 | Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer

Novel Immunotherapy for Pulmonary Remodeling Diseases

Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...

Published: 4/23/2026 | Inventor(s): Roger Johns

Keywords(s): Antibodies, Biologics, Cardiovascular Diseases, Disease Indication, Hypertension, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Hypertension

Monoclonal Antibody to Treat Autoinflammation Associated with Chronic Diseases

Published: 4/24/2026 | Inventor(s): Roger Johns

Keywords(s):

Formulation and sustained release of fat reduction small molecule

Value Proposition· Sustained release of small molecule that depletes white fat· Local injectable administration with less intense dosing regimenUnmet Need· Excessive white fat accumulation, commonly associated with obesity, is a significant health concern that impacts metabolic, cardiovascular, and endocrine systems. White adipose...

Published: 4/24/2026 | Inventor(s): Laura Ensign, Yub Raj Neupane, Fatemeh Rajaii

Keywords(s):

Category(s): Clinical and Disease Specializations > Endocrinology > Thyroid Disorders, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Small Molecules

Multispecific Antibodies that Induce Downregulation of Programmed Death-ligand 1

Unmet Need: It is estimated that in 2018 there were more than 17 million new cases of cancer worldwide (see ACS). Immune checkpoint therapies have become a powerful treatment route for a wide variety of cancer types and have increased the life expectancy for patients whose disease is refractory to all other therapies. Due to variability in patient response...

Published: 4/24/2026 | Inventor(s): Jamie Spangler, Seth Ludwig, Angela Zhu, Rakeeb Kureshi, Helen Dooley

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies

1 2 3 4